BPC-157 vs TB-500: Two Recovery Peptides, One With No Human Studies

BPC-157 and TB-500 are the two injectable peptides most often sold for tendon, muscle and joint recovery, and they are usually sold together. They are different molecules with different human records. BPC-157 is a 15-amino-acid peptide based on a protein found in gastric juice, and three small uncontrolled human reports exist for it.^[1][7] TB-500 is a seven-amino-acid fragment of the repair protein thymosin beta-4, and FDA found no study that gave TB-500 to a person.^[2] Neither is FDA-approved. Since October 28, 2026, both are in an interim HHS enforcement-discretion policy for 503A pharmacies, with different routes covered: BPC-157 acetate as an injection, capsule or topical product, and TB-500 acetate as an injection only.^[3]

BPC-157 vs TB-500 at a glance

What each peptide is

BPC-157 was developed in Croatia and first described in 1993. FDA’s 2026 review calls it a “pentadecapeptide fragment” of a protein originally isolated from human gastric juice, and notes that the names used for it do not follow standard chemical naming.^[1] The HHS policy identifies the covered form by its 15-amino-acid sequence and its acetate salt.^[3] Most of the research on it for injuries, on tendon, ligament, muscle, joint and bone, was done in small animals.^[11]

TB-500 is shorter and newer. It is a lab-made copy of seven amino acids (positions 17 to 23) of thymosin beta-4, a 43-amino-acid protein the body makes, with an acetyl group added at one end.^[2] Platelets release thymosin beta-4 at the site of an injury, which is why it has been studied for wound healing.^[9] The two are often treated as the same thing online, which orthopedic reviewers call a common mistake: no study has shown that the fragment does in people what the full protein does.^[11]

The human evidence for each

BPC-157: three small reports from one clinic group

FDA counted five clinical studies that used BPC-157, including enema studies, and found no human pharmacokinetic data for BPC-157 taken by mouth, under the skin, through the nose or through the skin.^[1] A 2026 systematic review of its use for injury and repair found three eligible human studies with 30 people in total, rated all three as poor quality and rated the certainty of the evidence as very low.^[7]

• Knee pain (2021). A Florida clinic looked back at charts and phoned 16 patients who had had a peptide injected into the knee. Of the 12 given BPC-157 alone, 11 said their pain improved significantly. There was no control group, and the authors write that no specific tools were used to measure improvement.^[4]
• Interstitial cystitis (2024). Twelve women with bladder pain that had not responded to pentosan polysulfate had 10 mg of BPC-157 injected into the bladder wall in one procedure. Ten reported complete resolution, and no adverse events were reported. Again there was no comparison group.^[5]
• IV safety (2025). Two adults who had used IV BPC-157 before received infusions of 10 mg and then 20 mg, with no measurable change in heart, liver, kidney, thyroid or glucose tests.^[6]

All three reports come from the same lead author. None tested an injection under the skin or into muscle for a tendon or muscle injury, the use BPC-157 is mainly sold for. The review’s authors concluded that BPC-157 should not be used in people outside regulated, high-quality clinical trials.^[7] The doses in these reports are covered in BPC-157 dosage in the studies.

TB-500: no human studies, and a parent protein with its own record

FDA searched the medical literature and “did not identify data, such as clinical studies, on the use of TB-500 in humans.” All three references submitted to support TB-500’s nomination were studies of full thymosin beta-4.^[2] FDA’s safety-risk page says the same: no human exposure data for the fragment.^[12]

The human data quoted for TB-500 belong to the full protein. In a phase 1 trial, 40 healthy volunteers received IV thymosin beta-4 or placebo at doses from 42 to 1,260 mg a day for 14 days, and adverse events were infrequent and mild or moderate.^[8] In two phase 2 trials in patients with venous stasis and pressure ulcers, thymosin beta-4 sped healing by almost a month in the patients whose ulcers healed.^[9] None of that was given as TB-500, and none was injected under the skin or into muscle, the routes the HHS policy covers. Our page on TB-500 side effects and dosing goes through those trials.

BPC-157 has three small uncontrolled human reports. TB-500 has none. Neither has a controlled human trial for an injury.

The one study that compared them

Only one controlled experiment we found gave BPC-157, TB-500 and both together to comparable groups, and it was in rats. A Turkish team cut and repaired the Achilles tendon in 32 rats and split them into four groups of eight: no treatment, BPC-157, TB-500, or both, injected into the abdomen daily for four weeks. Only the TB-500 group had significantly stronger tendons than untreated rats on the strength test. Both peptides improved some tissue scores, and the authors reported that the combination “did not confer additional benefits compared to either agent alone.”^[10]

That is a single small animal study with a short follow-up, and its authors call it exploratory. It does not tell anyone which peptide works better in people, because neither has been tested in people with this kind of injury. A 2026 review by orthopedic surgeons at NYU Langone and Baptist Health found no controlled human orthopedic evidence for BPC-157, thymosin beta-4 or TB-500, and concluded that routine clinical use “cannot be currently recommended.”^[11]

Regulatory status side by side

Both peptides went through the same FDA process in 2026. Each had been in FDA’s Category 2, substances raising significant safety concerns, from September 2023 until April 22, 2026, when the nominations were withdrawn. In July 2026 FDA staff told the Pharmacy Compounding Advisory Committee that the evidence weighed against putting either one on the 503A bulks list, the list of substances 503A pharmacies may compound from, and the committee voted in favor of both.^[1][2][3] FDA’s safety-risk page still lists both in its table of withdrawn nominations, with notes on possible immune reactions and impurities.^[12]

On October 28, 2026, HHS said it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding either peptide under section 503A, as long as every condition of its interim policy is met. The routes differ. For BPC-157 acetate the policy covers subcutaneous and intramuscular injections plus oral and topical products. For TB-500 acetate it covers the two injectable routes and nothing else.^[3] For TB-500, HHS said the safety concerns FDA staff raised were “inferential rather than observed” and pointed to the human record of the parent protein.^[3] The policy is not an approval, it lasts until a final rule decides each peptide’s listing, and it does not cover 503B outsourcing facilities.^[3][14] The HHS peptide compounding policy explainer lists every condition.

Research-use-only vials sold online are outside the policy for both peptides. The difference between those and a compounded product is set out in research-use-only vs compounded peptides.

In sport

Both are banned at all times under the World Anti-Doping Agency’s Prohibited List. BPC-157 is named in section S0, non-approved substances, and TB-500 in section S2.3, as a derivative of thymosin beta-4.^[13] A prescription from a compounding pharmacy does not change that for a tested athlete.

Safety: what is known about each

• BPC-157. The three human reports recorded no adverse events, but together they include 30 people, too few to detect anything uncommon.^[7] FDA’s notes cite possible immune reactions and impurity problems for some routes and say the agency cannot tell from the available data whether it would harm people.^[12] Its side effects are covered in BPC-157 side effects.
• TB-500. No human safety data exist for the fragment. FDA notes the same possible immune and impurity risks and says it lacks important information on whether TB-500 would cause harm in people.^[12] The tolerability seen in thymosin beta-4 trials does not transfer automatically to a different molecule given by a different route.^[11]
• Both. Product quality is a separate risk. Orthopedic reviewers flag identity, purity, concentration, sterility and manufacturing consistency as open questions for peptides sold online.^[11] The HHS policy requires a certificate of analysis for each bulk peptide, which a research-use-only vial does not carry.^[3]

Why people combine them, and what is known about that

Sellers pair the two on the theory that they work through different repair pathways, so together they should do more. The evidence for that is thin in both directions. In the 2021 knee chart review, four patients received BPC-157 with “TB4”, and three said their pain improved; the paper does not make clear whether that meant the full protein or the fragment.^[4] The rat study above is the only controlled test of the pairing, and it found no added benefit.^[10]

A pre-mixed BPC-157 and TB-500 vial is outside the HHS policy. Condition 7 requires that a compounded product contain “only a single Active Pharmaceutical Ingredient,” so a two-peptide vial does not qualify even though each peptide is on the list.^[3] A prescriber ordering two separate single-ingredient products is a different case, and each would have to meet every condition on its own, including a patient-specific prescription.^[3] FDA’s adverse event records already include a reaction to a two-peptide product that could not be pinned on either ingredient; that case is described in peptide blends and stacks. For how TB-500 compares with the copper peptide sold in the same blends, see TB-500 vs GHK-Cu.

To check where any other peptide stands, use our peptide status checker.